Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IMMUCELL CORP /DE/
Report date April 16, 2025 · Filed April 14, 2026
Section 16 reporting ended · disclosed 2026-04-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.49 · Expires 2030-04-16 | Direct | 10,000 |
Reported balance
After 2025-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-16 · Grant · Acquired 10,000 · Balance 10,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2025 Filed Apr 14, 2026 19:36 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantNon Qualified Stock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001437749-26-012232 · rdgdoc.xml · derivative · entry 1 Rosgen Steven T. · CIK 0001729885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-04-16 Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 12:29 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantNon Qualified Stock Options (Right to buy) · Derivative | 10,000 | $3.60 Strike: $3.60 | $36,000.00 |
DisclosureSEC source: 0001213900-24-081205 · marketforms-67043.xml · derivative · entry 1 Rosgen Steven T. · CIK 0001729885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-09-20 Read SEC document |
| December 15, 2022 Filed Jan 24, 2023 23:26 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantNon Qualified Stock Options (Right to buy) · Derivative | 10,000 | $6.52 Strike: $6.52 | $65,200.00 |
DisclosureSEC source: 0001213900-23-004912 · ownership.xml · derivative · entry 1 Rosgen Steven T. · CIK 0001729885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-12-15 Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 18:37 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantIncentive Stock Options (Right to buy) · Derivative | 10,000 | $10.04 Strike: $10.04 | $100,400.00 |
DisclosureSEC source: 0001213900-21-033251 · ownership.xml · derivative · entry 1 Rosgen Steven T. · CIK 0001729885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-06-17 Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 18:10 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantIncentive Stock Options (Right to buy) · Derivative | 15,000 | $7.08 Strike: $7.08 | $106,200.00 |
DisclosureSEC source: 0001213900-18-003255 · doc4.xml · derivative · entry 1 Rosgen Steven T. · CIK 0001729885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-03-19 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.